The Science
CurQD® is a botanical formulation composed of curcumin and Qing Dai (Indigo naturalis). Its development was informed by years of inquiry into plant-derived compounds and how they interact with the intestinal environment. Research groups across academic centers have examined this formulation through observational work, controlled trials, pediatric research, imaging-based evaluation, and combination-use studies.
The summaries below outline how investigators have described tolerability, participant-reported experience, biomarker patterns, and imaging-based observations.
The Studies
Initial Multicenter Study Evaluation in Adults
A multicenter observational study across five academic centers — published in Alimentary Pharmacology & Therapeutics in 2023 and republished in the Journal of Crohn’s and Colitis in 2025 — documented participant-reported experiences and biomarker trends during use of CurQD® among adults with gut issues.
ECCO Scientific Recognition
As of 2025, the European Crohn’s and Colitis Organisation (ECCO) has officially referenced CurQD® in its guidelines for gut discomfort after reviewing available scientific literature describing safety profiles, study methodology, and usage patterns reported in academic contexts.
Harvard Editorial Review
An editorial in Clinical Gastroenterology and Hepatology authored by a Harvard Medical School investigator, discussed the scientific design and relevance of a randomized controlled trial involving CurQD®.
Bowel Urgency Improvement
A post-hoc analysis published in Journal of Crohn’s & Colitis evaluated assessment-based measures related to bowel urgency using standardized scoring tools.
Study Focused on Individuals with Long-Standing Intestinal Challenges
A multicenter evaluation published in Journal of Crohn’s & Colitis in January 2025, with a secondary publication in Frontiers in Gastroenterology in July 2025, examined CurQD® as a botanical approach used alongside existing routines. Researchers monitored biomarker trends, participant feedback, and continuation rates.
Ultrasound-Based Study at University of Chicago
A retrospective study from the University of Chicago published in Journal of Crohn’s & Colitis in January 2025 used intestinal ultrasound imaging and laboratory markers to document eight-week observational findings.
Prolonged Multicenter International Pediatric Study
A study published in 2024 in Frontiers in Pediatrics evaluated CurQD® among children and adolescents, documenting tolerability, biomarker patterns, and participant-reported observations across both an induction and extended follow-up phase.
International Multicenter Study
A double-blind, placebo-controlled trial conducted in Greece and Israel, published in Clinical Gastroenterology and Hepatology in 2024 assessed CurQD® over blinded and maintenance periods while tracking biological and participant-reported indicators.
Pediatric Gut Issues Case Series
A case series conducted at Children’s Hospital Los Angeles and published in Inflammatory Bowel Diseases in 2024 documented short-term observations among adolescents incorporating CurQD® alongside existing care routines.
European Study: Vedolizumab + CurQD® Combination
A European prospective study published in Inflammatory Bowel Diseases in 2025 explored the concurrent use of Vedolizumab with CurQD®, including participant reports, biochemical markers, and endoscopic scoring.
Pediatric Safety Study on CurQD®
A prospective open-label study from Rabin Medical Center published in Inflammatory Bowel Diseases in 2025, observed short-term tolerability and scoring patterns among pediatric participants.
Long-Term Individual Case Report
A case report published in Case Reports in Gastroenterology in 2025 described prolonged, continued use of CurQD® with scheduled clinical follow-up evaluations over an extended period.